Explore 3 Stock Ideas & Industry Insights Download Free Report

Pediatrix Medical Group, Inc.

Company price
30.225 USD 0.28 ( 0.95%)
Last update at 2026-11-20T21:00:00Z
VOLUME
600303
Market Cap
2168.65M
P/E
12.89

Momentum Score

…

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
29.89
Low
30.43
High
52 Week Price Range
15.70
Low
27.94
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
29.94
Dividend Yield
-
Revenue TTM
1950.63M
Revenue Per Share
23.87
Gross Profit TTM
511.77M
Debt / Equity
0.76
ROE
20.39%
Net Debt
285.06M
ROCE
14.12%
Diluted EPS TTM
2.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 216.43M -101.34M -48.36M 81.37M 135.23M
Minority interest - 0.00M 0.00M 0.00M 0.03M
Net income 165.39M -99.07M -60.41M 66.33M 130.96M
Selling general administrative 240.79M 238.44M 227.54M 231.40M 263.36M
Gross profit 471.88M 454.34M 421.56M 467.03M 513.24M
Reconciled depreciation 21.83M 32.23M 36.17M 35.64M 32.15M
Ebit 252.40M -60.60M -6.28M 172.69M 202.92M
Ebitda 274.22M -28.37M 29.89M 237.36M 251.80M
Depreciation and amortization 21.83M 32.23M 36.17M 64.67M 48.88M
Non operating income net other - - - -56.67M 15.56M
Operating income 231.09M -68.71M 7.32M 172.69M 202.92M
Other operating expenses 1682.76M 2081.63M 1987.32M 1772.02M 1693.45M
Interest expense 35.97M 40.74M 42.08M 39.70M 68.72M
Tax provision 51.04M -2.27M 12.05M 18.81M 27.24M
Interest income 13.29M 32.63M 35.68M 34.30M 53.16M
Net interest income -35.97M -40.74M -42.08M -39.70M -68.72M
Extraordinary items - 0.00M 0.00M 3.77M 22.95M
Non recurring - - - 27.31M 22.10M
Income tax expense 51.04M -2.27M 12.05M 18.81M 27.24M
Total revenue 1913.85M 2012.92M 1994.64M 1972.02M 1911.19M
Total operating expenses 240.79M 523.06M 414.24M 267.03M 295.50M
Cost of revenue 1441.97M 1558.58M 1573.08M 1504.99M 1397.95M
Total other income expense net -14.65M -32.63M -55.68M -91.32M -67.69M
Discontinued operations - - - 3.77M 22.95M
Net income from continuing ops 165.39M -99.07M -60.41M 62.56M 107.99M
Net income applicable to common shares 165.39M -99.07M -60.41M 66.33M 130.96M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2246.70M 2152.70M 2219.81M 2347.89M 2722.55M
Intangible assets 16.86M 11.60M 21.24M 18.49M 21.57M
Other current assets 21.48M 18.50M 25.83M 28.14M 51.68M
Total liab 1380.84M 1387.76M 1370.75M 1456.26M 1825.85M
Total stockholder equity 865.85M 764.94M 849.06M 891.63M 896.69M
Deferred long term liab - - - 33.64M 41.41M
Other current liab 382.31M 316.81M 279.67M 199.96M -22.17M
Common stock 0.83M 0.86M 0.84M 0.83M 0.86M
Capital stock 0.83M 0.86M 0.84M 0.83M 0.86M
Retained earnings -83.15M -248.54M -149.47M -89.06M -155.39M
Other liab - - - 348.68M 365.91M
Good will 1260.73M 1242.61M 1384.17M 1834.48M 1794.96M
Other assets 121.33M 180.45M 185.02M 229.10M 219.37M
Cash 375.24M 229.94M 73.26M 9.82M 387.39M
Cash and equivalents 375.24M 229.94M 73.26M 9.82M 387.39M
Total current liabilities 458.91M 434.11M 388.95M 374.23M 394.12M
Current deferred revenue - - -32.43M 105.92M -
Net debt 285.06M 432.37M 628.39M 743.74M 678.44M
Short term debt 38.40M 33.25M 35.99M 36.49M 22.17M
Short long term debt 25.00M 18.75M 12.50M 14.90M -
Short long term debt total 660.30M 662.31M 701.65M 753.57M 1065.83M
Other stockholder equity 947.57M 1013.69M 999.91M 983.60M 1049.90M
Property plant equipment 73.51M 78.44M 145.93M 73.29M 70.15M
Total current assets 763.51M 639.61M 483.45M 334.75M 740.85M
Long term investments - - - 93.24M 99.72M
Net tangible assets - - - 891.63M 896.49M
Short term investments 124.48M 118.57M 104.48M 93.24M 99.72M
Net receivables 242.31M 272.60M 279.88M 296.79M 301.77M
Long term debt 568.95M 593.57M 611.59M 636.38M 1002.26M
Inventory - - 13.53M - -
Accounts payable 37.22M 46.43M 34.59M 31.86M 394.12M
Noncontrolling interest in consolidated entity - - - - 0.20M
Accumulated other comprehensive income 0.61M -1.07M -2.21M -3.73M 1.32M
Common stock total equity - - - 0.83M 0.86M
Retained earnings total equity - - - -89.06M -155.39M
Non currrent assets other 37.36M 76.60M 82.17M -105.92M -88.34M
Non current assets total 1483.18M 1513.09M 1736.36M 2013.14M 1981.70M
Capital lease obligations 40.66M 49.99M 77.56M 65.80M 63.57M
Long term debt total 570.53M 597.12M 618.42M 636.38M 1002.26M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -3.18M -35.41M -46.99M -56.95M 1.44M
Change to liabilities - - - -1.35M -3.48M
Total cashflows from investing activities -18.30M -35.41M -48.18M -56.95M -53.07M
Net borrowings -20.75M -15.39M -19.12M -401.50M -759.85M
Total cash from financing activities -107.49M -14.48M -25.71M -487.55M -760.12M
Change to operating activities - - - 18.73M 30.32M
Net income 165.39M -99.07M -60.41M 62.57M 108.01M
Change in cash 145.30M 156.68M 63.43M -377.57M -736.45M
Begin period cash flow 229.94M 73.26M 9.82M 387.39M 1123.84M
End period cash flow 375.24M 229.94M 73.26M 9.82M 387.39M
Total cash from operating activities 271.09M 206.57M 137.32M 166.94M 76.74M
Issuance of capital stock 3.18M 3.64M 5.05M 5.40M 6.85M
Depreciation 21.83M 33.18M 36.17M 35.64M 32.15M
Other cashflows from investing activities -3.46M 6.83M 0.81M -26.79M 84.87M
Dividends paid - - 470.00M - -
Change to account receivables 30.56M 10.29M 26.28M -5.54M -72.73M
Sale purchase of stock -86.68M -1.70M -0.92M -88.51M -4.72M
Other cashflows from financing activities -3.25M -1.03M -10.59M 1480.73M 0.41M
Change to netincome - - - 31.38M -14.16M
Capital expenditures 18.46M 22.02M 33.33M 29.71M 32.25M
Change receivables - - - -5.54M -72.73M
Cash flows other operating - - - 38.72M 52.84M
Cash and cash equivalents changes - - - -377.57M -736.45M
Change in working capital 41.83M 88.24M -11.63M 31.83M -23.36M
Stock based compensation 18.05M 11.87M 12.32M 16.13M 18.97M
Other non cash items -28.18M 174.49M 157.63M 43.55M -27.80M
Free cash flow 252.63M 184.55M 104.00M 137.23M 44.49M

Peer Comparison*

Sector: Healthcare Industry: Medical Care Facilities

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MD
Pediatrix Medical Group, Inc.
0.28
0.95%
30.23 12.89 8.21 1.11 2.48 1.23 8.48
HCA
HCA Healthcare, Inc.
15.19
3.30%
475.52 14.27 13.46 1.21 291.34 1.83 8.99
THC
Tenet Healthcare Corporation
-0.10
0.04%
263.49 10.08 12.66 0.96 4.57 1.43 5.80
FSNUY
Fresenius SE & Co KGaA ADR
-0.22
1.52%
14.00 16.87 9.44 0.42 0.78 0.79 5.37
JDHIY
JD Health International Inc
1.31
30.75%
5.57 62.50 35.97 0.30 2.32 0.16 3.90

Profile*

Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

1301 Concord Terrace, Sunrise, FL, United States, 33323

954 384 0175

4280

Name Title Year Born
Mr. Mark S. Ordan CEO & Director 1959
Dr. Roger J. Medel M.D. Co-Founder & Director 1947
Mr. C. Marc Richards Exec. VP & CFO 1971
Mr. John C. Pepia Sr. VP & Chief Accounting Officer 1963
Ms. Mary Ann E. Moore Exec. VP and Chief Enterprise Risk & Legal Operations Officer 1960
Dr. James D. Swift M.D. Exec. VP & Chief Operating Officer NA
Ms. Cheryl M. VanPattan Sr. VP & Chief Information Officer NA
Mr. Charles W. Lynch C.F.A. Sr. VP of Fin., Strategy & Investor Relations NA
Ms. Dana Dreher-Rodwell VP & Chief Compliance Officer NA
Ms. Meghan K. Lublin Sr. VP, Chief Brand & Communications Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…